Satralizumab

Tax included
Satralizumab, a humanized monoclonal antibody, is a potent Interleukine-6 (IL-6) inhibitor. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research.
MedChemExpress 
HY-P99112

Data sheet

Size
Multiple sizes
Reactivity
Interleukin Related
Application
COVID-19-immunoregulation
CAS
1535963-91-7